Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Blood (2024) 144 (15): 1570–1580.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Blood (2024) 144 (9): 988–1000.

https://doi.org/10.1182/blood.2023022154

Published: 2024

Includes: Supplemental data

Journal Articles

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Blood (2023) 142 (Supplement 1): 844.

https://doi.org/10.1182/blood-2023-179298

Published: 2023

Journal Articles

Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

Blood (2023) 142 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2023-185831

Published: 2023

Journal Articles

Efficacy and Tolerance of the BNT162b2 Vaccine in Children with Acute Leukemia and Their Siblings: Results of the Phase I-II Pacific Trial

Fanny Alby Laurent, Amani Ouedrani, Pierre Jatteau, Marion Strullu, Claire Montlahuc, Chaima Mrad, Audrey Guilmatre, Maxime Ferreboeuf, Anne-France Ray-Lunven, Florentia Kaguelidou, Lucienne Chatenoud, Laurence Morand-Joubert, Sylvie Chevret, Arnaud Petit

Blood (2023) 142 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2023-181899

Published: 2023

Journal Articles

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Blood (2023) 142 (Supplement 1): 730.

https://doi.org/10.1182/blood-2023-181593

Published: 2023

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network

Adriana Plesa, Octavia Cadassou, Joris Gutrin, Marine Villard, Christophe Roumier, Meyling Cheok, Florent Dumezy, Claude Preudhomme, Hélène Lapillonne, Arnaud Petit, Guy Leverger, Carine Halfon-Domenech, Cecile Renard, Yves Bertrand, Charles Dumontet, Sebastien Viel, Veronique Maguer-Satta, Thierry Walzer

Blood (2021) 138 (Supplement 1): 2375.

https://doi.org/10.1182/blood-2021-154181

Published: 2021

Journal Articles

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Blood (2021) 138 (Supplement 1): 1231.

https://doi.org/10.1182/blood-2021-145476

Published: 2021

Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Blood (2021) 138 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2021-145709

Published: 2021

Journal Articles

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

Mathieu Simonin, Ludovic Lhermitte, Marie-Emilie Dourthe, Etienne Lengliné, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Isabelle Arnoux, Virginie Gandemer, Norbert Ifrah, Hervé Dombret, André Baruchel, Elizabeth Macintyre, Arnaud Petit, Nicolas Boissel, Vahid Asnafi

Blood (2021) 137 (12): 1690–1694.

https://doi.org/10.1182/blood.2020007959

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134774

Published: 2020

Journal Articles

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

Seth E. Karol, MD, Henrique Bittencourt, MD PhD, Daniel A. Morgenstern, MD, Margaret E. Macy, MD, Seong Lin Khaw, MD, Todd M. Cooper, DO, Arnaud Petit, MD PhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Andrew E. Place, MDPhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136999

Published: 2020

Journal Articles

Caution encouraged in next-generation sequencing immunogenetic analyses in acute lymphoblastic leukemia

Chrystelle Abdo, Florian Thonier, Mathieu Simonin, Sophie Kaltenbach, Julie Valduga, Arnaud Petit, Monika Brüggemann, Elizabeth Macintyre

Blood (2020) 136 (9): 1105–1107.

https://doi.org/10.1182/blood.2020005613

Published: 2020

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

NARROW

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

Efficacy and Tolerance of the BNT162b2 Vaccine in Children with Acute Leukemia and Their Siblings: Results of the Phase I-II Pacific Trial

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

Caution encouraged in next-generation sequencing immunogenetic analyses in acute lymphoblastic leukemia

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only